Belatacept in kidney transplantation

David Wojciechowski, Flavio Vincenti

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


PURPOSE OF REVIEW: In June 2011 the US Food and Drug Administration approved belatacept (Nulojix; Bristol-Myers Squibb, Princeton, New Jersey, USA) for the prophylaxis of organ rejection in adult kidney transplant recipients. This review will discuss the use of belatacept for the prevention of acute rejection as part of a maintenance immunosuppression regimen. RECENT FINDINGS: Belatacept is a selective costimulation blocker designed to provide effective immunosuppression while avoiding the toxicities associated with calcineurin inhibitors. Phase 3 trial data have demonstrated that belatacept is noninferior to cyclosporine in 1-year patient and allograft survival. Three-year data demonstrate an ongoing improvement in mean measured glomerular filtration rate in belatacept-treated versus cyclosporine-treated patients. Overall, there seemed to be an improvement in cardiometabolic parameters in patients treated with belatacept compared with cyclosporine. There was a trend toward higher rates of early rejection episodes in patients treated with belatacept. One safety issue that must be considered when using belatacept is the potential for increased risk of posttransplant lymphoproliferative disease, especially in Epstein-Barr virus-seronegative recipients or patients treated with lymphocyte-depleting agents. SUMMARY: Belatacept is the first new agent available in kidney transplant that may achieve the goal of improved long-term renal function.

Original languageEnglish (US)
Pages (from-to)640-647
Number of pages8
JournalCurrent Opinion in Organ Transplantation
Issue number6
StatePublished - Dec 1 2012
Externally publishedYes


  • belatacept
  • costimulation
  • kidney transplant

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation


Dive into the research topics of 'Belatacept in kidney transplantation'. Together they form a unique fingerprint.

Cite this